RESUMO
BACKGROUND: To evaluate the impact of dihydrofolate reductase (DHFR) and reduced folate carrier (RFC) genes on methotrexate (MTX) resistance in osteosarcoma cells in relation to retinoblastoma (RB1) gene status. MATERIALS AND METHODS: A series of human osteosarcoma cell lines-either sensitive or resistant to MTX-and 16 osteosarcoma tumour samples were used in this study. RESULTS: In U-2OS MTX-resistant variants, and in other RB1-positive cell lines, MTX resistance was associated with increased levels of DHFR and with a slight decrease of RFC gene expression. In Saos-2 MTX-resistant variants, and in another RB1-negative cell line, development of MTX resistance was associated with a decrease in expression of RFC, without any significant involvement of DHFR. In osteosarcoma clinical samples, amplification of the DHFR gene at clinical onset appeared to be more frequent in RB1-positive compared with RB1-negative tumours. CONCLUSIONS: Amplification of the DHFR gene may occur more frequently in the presence of RB1-mediated negative regulation of its activity and can be present at clinical onset in osteosarcoma patients. Simultaneous evaluation of RFC, DHFR and RB1 gene status at the time of diagnosis may become the basis for the identification of potentially MTX-unresponsive osteosarcoma patients, who could benefit from treatment protocols with alternative antifolate drugs.
Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Resistencia a Medicamentos Antineoplásicos/genética , Hexosiltransferases/genética , Proteínas de Membrana Transportadoras/genética , Metotrexato/farmacologia , Osteossarcoma/genética , Proteína do Retinoblastoma/genética , Tetra-Hidrofolato Desidrogenase/genética , Amplificação de Genes , Deleção de Genes , Regulação Neoplásica da Expressão Gênica , Humanos , Técnicas In Vitro , Proteínas de Membrana , Osteossarcoma/tratamento farmacológico , Osteossarcoma/metabolismo , RNA Mensageiro , Proteína Carregadora de Folato Reduzido , Células Tumorais CultivadasRESUMO
Relatively little is known about the biologic relevance of numerical chromosomal changes in relation to DNA content in osteosarcoma. In this study, by using a series of human osteosarcoma cell lines, we standardized a method for the assessment, on the same nuclei specimen, of both specific chromosome copy numbers by fluorescence in situ hybridization (FISH) and the DNA content by static cytofluorometry or image cytometry. On the same cell lines, we also evaluated the DNA content by using flow cytometry and the chromosome number distribution by metaphase analysis. Comparison between these different methods showed that DNA ploidy level as determined by FISH or metaphase analysis is frequently lower than the ploidy pattern as defined by cytometric methods. By using comparative genomic hybridization, we were able to demonstrate that these discrepancies were due to the presence of several unbalanced chromosome aberrations, specifically gains and high-level amplifications, which affect the total DNA content with less effect on the total chromosome number. Thus, evaluation of DNA ploidy in osteosarcoma cells is needed for a correct interpretation of FISH or cytogenetic data concerning numerical chromosomal changes. Evaluation of tumor ploidy in a series of clinical samples demonstrated that in high-grade osteosarcoma, flow cytometry sometimes may give false results because of the presence of high proportions of contaminating, nonneoplastic cells that cannot be excluded from the flow cytometric assessment but that do not interfere with the evaluation of DNA ploidy by static cytofluorometry or image cytometry, in which only tumor cells are selected for the analysis. The possibility of using this method to evaluate, on the same nuclei sample, both specific chromosomal aberrations and DNA ploidy may allow a better determination of numerical chromosomal changes that may be relevant for the biologic behavior of osteosarcoma.
Assuntos
Neoplasias Ósseas/genética , Aberrações Cromossômicas/genética , DNA de Neoplasias/metabolismo , Osteossarcoma/genética , Neoplasias Ósseas/patologia , DNA de Neoplasias/genética , Citometria de Fluxo , Humanos , Hibridização in Situ Fluorescente , Osteossarcoma/patologia , Ploidias , Células Tumorais CultivadasRESUMO
Many p53 mutants found in human cancer have an altered ability to bind DNA and transactivate gene expression. Re-expression of functional p53 in cells in which the endogenous TP53 gene is inactivated has been demonstrated to restore a non-tumorigenic phenotype. Pharmacological modulation of p53 mutant conformation may therefore represent a mechanism to reactivate p53 function and consequently improve response to radio- and chemotherapy. We have recently reported that the radio- and chemoprotector Amifostine (WR2721, Ethyol) activates wild-type p53 in cultured mammalian cells. In the present study, we have used a yeast functional assay to investigate the effect of WR2721 on the transcriptional activity of p53. WR2721 restored this activity in a temperature-sensitive mutant V272M (valine to methionine at codon 272) expressed at the non-permissive temperature and it also partially restored the transcriptional activity of several other conformationally flexible p53 mutants. The results indicate that the yeast functional assay may be used to identify compounds that modulate p53 activity, with potential therapeutic implications.
Assuntos
Amifostina/farmacologia , Protetores contra Radiação/farmacologia , Transcrição Gênica/efeitos dos fármacos , Proteína Supressora de Tumor p53/química , Proteína Supressora de Tumor p53/metabolismo , Substituição de Aminoácidos , Animais , Clonagem Molecular , Códon , Neoplasias Esofágicas/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Mamíferos , Metionina , Modelos Moleculares , Mutagênese Sítio-Dirigida , Poliaminas/farmacologia , Reação em Cadeia da Polimerase , Regiões Promotoras Genéticas , Conformação Proteica , Estrutura Secundária de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Saccharomyces cerevisiae/crescimento & desenvolvimento , Temperatura , Células Tumorais Cultivadas , Proteína Supressora de Tumor p53/genética , ValinaRESUMO
Adenocarcinoma of the esophagus (ADCE) with Barrett's mucosa and adenocarcinoma of the cardia (ADCC) are often reported as a single pathological entity. In this study we have used strict anatomical-pathological criteria to distinguish between these two lesions and we have investigated their differences in TP53 mutations, MDM2 gene amplification, and cytokeratin expression. DNA was extracted from the tumor areas of formalin-fixed, paraffin-embedded sections in 26 ADCC and 28 ADCE patients. TP53 mutations were detected by temporal temperature gradient electrophoresis and identified by sequencing. MDM2 amplification was assessed by differential polymerase chain reaction. The expression of cytokeratins 4, 7, and 13 was examined by immunohistochemistry. In ADCC, the male to female ratio was 1.8:1, compared to 27:1 in ADCE. Five ADCC patients had a history of other neoplasms, compared to only one ADCE patient. The two types of tumor differed in the prevalence of TP53 mutations (31% in ADCC and 50% in ADCE) and of MDM2 gene amplification (19% in ADCC and 4% in ADCE), and in the pattern of expression of cytokeratin 7 (positive in 100% of ADCE and in 41% of ADCC) and cytokeratin 13 (positive in 81% of ADCE and in 36.5% of ADCC). ADCE and ADCC differ in their clinical characteristics, in the prevalence of TP53 mutations and MDM2 amplifications, and in the patterns of cytokeratin expression. These results support the notion that ADCC and ADCE are distinct pathological entities.
Assuntos
Adenocarcinoma/patologia , Cárdia/patologia , Neoplasias Esofágicas/patologia , Proteínas Nucleares , Neoplasias Gástricas/patologia , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Cárdia/química , Cárdia/metabolismo , Diagnóstico Diferencial , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/metabolismo , Feminino , Mucosa Gástrica/química , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patologia , Amplificação de Genes , Regulação Neoplásica da Expressão Gênica , Humanos , Queratina-7 , Queratinas/análise , Masculino , Pessoa de Meia-Idade , Mutação , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas c-mdm2 , Neoplasias Gástricas/genética , Neoplasias Gástricas/metabolismo , Proteína Supressora de Tumor p53/análise , Proteína Supressora de Tumor p53/genéticaRESUMO
Alkaline phosphatases are a family of glycoproteins that are able to hydrolize various monophosphate esters at a high pH optimum. Liver/bone/kidney (L/B/K) alkaline phosphatase (ALP) is one of the four major isoenzymes that belong to this family. Apart from its role in normal bone mineralization, other functions of L/B/K ALP remain obscure, both in physiological and in neoplastic conditions, including the bone-forming tumor osteosarcoma. In this study, we transfected the U-2 OS osteosarcoma cell line, which does not show any basal expression of this enzyme, with the full-length gene of L/B/K ALP, and analyzed the in vitro and in vivo features of four transfectants showing different expression of L/B/K ALP. A reduced in vitro ability to invade Matrigel and to grow in a semi-solid medium, together with a lower tumorigenic and metastatic ability in athymic mice, was found to be associated with a high level of cell surface L/B/K ALP activity. Moreover, L/B/K ALP transfectants showed a reduced secretion of matrix metalloproteinase-9 enzyme. These findings indicate a loss of aggressiveness of osteosarcoma cells after the expression of L/B/K ALP on their surface and suggest a new role for this enzyme.
Assuntos
Fosfatase Alcalina/genética , Osteossarcoma/genética , Transdução Genética , Animais , Quimiotaxia , Humanos , Camundongos , Osteossarcoma/enzimologia , Osteossarcoma/patologia , Fenótipo , Células Tumorais CultivadasRESUMO
The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-effect relationship with the reduced metastatic potential of MDR cells, or rather reflects a more complex phenotype. MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the different levels of P-glycoprotein, no significant change in the expression of surface antigens or in the differentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a significantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Osteossarcoma/fisiopatologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Animais , Humanos , Camundongos , Camundongos Nus , Fenótipo , Transfecção , Células Tumorais CultivadasRESUMO
The transcription of MDR1 gene may be increased by mutation or loss of function of p53 gene. In this study, we investigated whether in osteosarcoma, the p53 status is correlated with overexpression of the MDR1 gene product P-glycoprotein. The relationship between P-glycoprotein expression and p53 status was analyzed by immunohistochemistry in 64 primary and 11 metastatic high-grade osteosarcomas. In the same series, we also assessed the nuclear accumulation of MDM2 protein, whose binding to p53 protein provides an alternative mechanism of p53 inactivation. No association was found between mutant-p53 and MDM2 nuclear accumulation either with P-glycoprotein expression or with clinical course. Only increased expression of P-glycoprotein in tumor cells was significantly associated with a poor outcome, further supporting the adverse prognostic value of this marker in osteosarcoma.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Biomarcadores Tumorais , Neoplasias Ósseas/genética , Osteossarcoma/genética , Proteína Supressora de Tumor p53/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Adolescente , Adulto , Neoplasias Ósseas/patologia , Criança , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Metástase Neoplásica , Osteossarcoma/patologia , Prognóstico , Proteína Supressora de Tumor p53/biossínteseRESUMO
Ewing sarcoma (ES) is the second most common primary malignant tumor of bone in children and young adolescents. Most ES contain a pathognomonic translocation t(11;22)(q24;q12) that is likely a pivotal event in the tumorigenesis of these neoplasms. Many ES also contain nonrandom, numerical chromosomal aberrations, the most common of which are trisomies 8 and 12. In this study we evaluated the hypothesis that these trisomies might occur during neoplastic progression and might be associated with differences in biologic behavior. We tested this hypothesis using a combined cytogenetic and dual color fluorescence in situ hybridization approach to determine chromosome 8 and 12 copy number in 52 ES. Relative gains, primarily trisomies, of chromosomes 8 and 12 were found in 24 (46%) and 17 (33%) cases, respectively. Trisomy 8 and trisomy 12 were independent events acquired in a flexible order during ES genetic progression. Our preliminary findings also suggest a higher frequency of trisomies 8 and 12 in relapses than in primary tumors. Prospective studies will be required to determine whether either trisomy is prognostic in newly-diagnosed ES.
Assuntos
Cromossomos Humanos Par 12 , Cromossomos Humanos Par 8 , Sarcoma de Ewing/genética , Adolescente , Adulto , Criança , Feminino , Humanos , Hibridização in Situ Fluorescente , Cariotipagem , MasculinoRESUMO
Metanephric adenoma is a recently described benign renal neoplasm with distinctive histologic features. The cytologic appearance and fluorescence in situ hybridization (FISH) studies of this tumor have not been described. We present a case from a 48-yr-old woman. Cytologically, the cells were arranged in tight, short papillae and loose sheets. The cells had scant cytoplasma, round monotonous nuclei with fine even chromatin and rare small nucleoli. Immunohistochemistry revealed no reactivity for epithelial membrane antigen (EMA), keratins (AE1/AE3, callus, 34BE12), or carcinoembryonic antigen (CEA). FISH showed a disomic pattern for chromosomes 7, 17, and for the chromosome 3 short arm. The differential diagnosis includes Wilms' tumor, renal adenoma, papillary renal cell carcinoma, and metastatic tumors. Both immunohistochemistry and FISH may be of help in distinguishing some of these lesions.
Assuntos
Adenoma/patologia , Neoplasias Renais/patologia , Adenoma/química , Carcinoma Papilar/diagnóstico , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Hibridização in Situ Fluorescente , Queratinas/análise , Neoplasias Renais/química , Pessoa de Meia-Idade , Mucina-1/análise , Metástase Neoplásica/diagnóstico , Tomografia Computadorizada por Raios X , Tumor de Wilms/diagnósticoRESUMO
The disappointingly low survival rate observed in Ewing's sarcoma (ES)/peripheral neuroectodermal tumor (PNET) despite the adoption of aggressive multimodal treatments prompted us to study the existence of autocrine circuits to be used as innovative therapeutic targets. Of the several circuits analyzed, only the insulin-like growth factor receptor (IGF-IR)-mediated loop was found to be constantly present both in cell lines and clinical samples, suggesting a role for this autocrine circuit in the pathogenesis of ES/PNET. The in vitro inhibition of the IGF-IR-mediated circuit by the specific IGF-IR binding antibody alphaIR3 suppressed the growth of ES/PNET cells by decreasing the proliferative rate and increasing apoptosis. alphaIR3 also significantly inhibited the ability of ES/PNET cells to grow in soft agar and to migrate following a chemotactic stimulus. Inactivation of the IGF-IR signaling pathway may therefore be considered as an effective therapeutic modality for patients with ES/PNET.
Assuntos
Neoplasias Ósseas/metabolismo , Fator de Crescimento Insulin-Like I/metabolismo , Tumores Neuroectodérmicos Primitivos Periféricos/metabolismo , Receptor IGF Tipo 1/metabolismo , Sarcoma de Ewing/metabolismo , Anticorpos/farmacologia , Movimento Celular , Humanos , Receptor IGF Tipo 1/antagonistas & inibidores , Fator de Crescimento Transformador beta/metabolismo , Células Tumorais CultivadasRESUMO
The identification of Ewing's sarcoma (ES) and peripheral neuroectodermal tumor (PNET) among other small round cell tumors (SRCTs) is a critical issue in musculoskeletal pathology because of the lack of clearly distinctive morphological features. In this study, the authors have compared advantages and limits of two procedures that were recently suggested as additional tools for the identification of ES/PNET, the analysis of p30/32MIC2 antigen by immunohistochemistry, and the evaluation of the fusion products of two specific chromosomal aberrations, the t(11;22)(q24;q12) and the t(21;22)(q22;q12), by reverse transcriptase-polymerase chain reaction (RT-PCR). The authors have analyzed the expression of p30/32MIC2 in 28 cell lines and in 90 tumor samples. p30/32MIC2 was highly expressed in ES/PNET but was also present in all the other cell types. The broad spectrum of positivity for p30/32MIC2 in SRCTs of bone was substantially confirmed by the analysis of tissue samples. In the same material, the authors have evaluated the presence of t(11;22) or t(21;22) transcripts (EWS/FLI-1 and EWS/ERG, respectively) by RT-PCR. These transcripts were found in all the cell lines and tissue samples of ES/PNET, but not in other tumors. The authors' results question the use of p30/32MIC2 immunostaining alone for the identification of ES/PNET and suggest the adoption of RT-PCR as an advantageous alternative. Molecular diagnosis of ES/PNET by RT-PCR is highly specific and can be applied to small amounts of tissue. Moreover, RNA extracted from paraffin-embedded specimens was shown to be suitable for RT-PCR analysis, thus enabling analysis of archival material.
Assuntos
Neoplasias Ósseas/diagnóstico , Rearranjo Gênico , Imuno-Histoquímica/métodos , Tumores Neuroectodérmicos Primitivos Periféricos/diagnóstico , Sarcoma de Ewing/diagnóstico , Neoplasias de Tecidos Moles/diagnóstico , Adolescente , Adulto , Anticorpos Monoclonais , Antígenos de Neoplasias/biossíntese , Biomarcadores Tumorais/análise , Neoplasias Ósseas/genética , Neoplasias Ósseas/patologia , Neoplasias Ósseas/secundário , Criança , Feminino , Citometria de Fluxo , Humanos , Masculino , Tumores Neuroectodérmicos Primitivos Periféricos/genética , Tumores Neuroectodérmicos Primitivos Periféricos/patologia , Reação em Cadeia da Polimerase , Sarcoma de Ewing/genética , Sarcoma de Ewing/patologia , Neoplasias de Tecidos Moles/genética , Neoplasias de Tecidos Moles/patologia , Transcrição Gênica , Células Tumorais CultivadasRESUMO
Soft tissue sarcomas comprise a heterogeneous group of mesenchymal tumors accounting for less than one-percent of adult neoplasms. In the last few years, the use of adjuvant chemotherapy has been proposed for the treatment of these lesions in order to obtain a better systemic control, but its usefulness is still controversial. In this study, we evaluated whether P-glycoprotein, a membrane protein strictly associated with multidrug resistance, is overexpressed in soft tissue sarcomas. By using human multidrug resistant sarcoma cell lines as controls, we analyzed P-glycoprotein expression in 34 primary and in 23 relapsed soft tissue sarcomas of the extremities. Overexpression of P-glycoprotein was found in 6 out of 34 primaries (18%) and in 8 out of 23 relapses (35%). In particular, in malignant fibrous histiocytoma, the most frequent soft tissue sarcoma of adults, P-glycoprotein overexpression was found in 23% of primary untreated cases, in agreement with the reported relapse rate of this tumor after surgery and chemotherapy. These data suggest that, in soft tissue sarcomas, overexpression of P-glycoprotein may be of prognostic value and that the assessment of P-glycoprotein expression may be useful for the design of chemotherapy protocols.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/biossíntese , Resistência a Múltiplos Medicamentos/genética , Resistencia a Medicamentos Antineoplásicos/genética , Regulação Neoplásica da Expressão Gênica , Proteínas de Neoplasias/biossíntese , Sarcoma/metabolismo , Neoplasias de Tecidos Moles/metabolismo , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Adulto , Extremidades , Histiocitoma Fibroso Benigno/tratamento farmacológico , Histiocitoma Fibroso Benigno/genética , Histiocitoma Fibroso Benigno/metabolismo , Humanos , Proteínas de Neoplasias/genética , Sarcoma/classificação , Sarcoma/tratamento farmacológico , Sarcoma/genética , Neoplasias de Tecidos Moles/tratamento farmacológico , Neoplasias de Tecidos Moles/genéticaRESUMO
The expression of osteonectin, osteopontin, bone sialoprotein, and osteocalcin was evaluated by immunohistochemistry in 57 cases of osteoid-forming and non-osteoid-forming bone tumours using specific polyclonal antibodies and the avidin-biotin peroxidase complex method. A positive immunostaining was found in all of the osteoid-forming rumours (osteoblastoma and osteosarcoma), both in the cells and in the extracellular matrix. Among non-osteoid-forming tumours, immunoreactivity to noncollagenous proteins was present in the cells but not in the matrix of chondrosarcoma, malignant fibrous histiocytoma, and fibrosarcoma, as well as in the mononuclear component of giant-cell rumours. Contrary to small-cell osteosarcoma, Ewing's sarcoma was always negative for all of the noncollagenous proteins considered. These results suggest that the immunohistochemical evaluation of noncollagenous proteins of bone may be a useful tool for the differential diagnosis of bone neoplasms, particularly among the heterogeneous group of small round cell tumours.
RESUMO
BACKGROUND: Increased levels of P-glycoprotein occur in some osteosarcomas. In this study we determined the relation between P-glycoprotein status and outcome in patients with high-grade osteosarcoma. METHODS: P-glycoprotein status was determined immunohistochemically in specimens of osteosarcoma of the extremities (stage II) from 92 patients who were treated with surgery and chemotherapy. The P-glycoprotein status was analyzed in relation to the length of event-free survival. RESULTS: The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P = 0.002). In a multivariate analysis, P-glycoprotein status (P = 0.001) and the extent of tumor necrosis after preoperative chemotherapy (P = 0.04) were independent predictors of clinical outcome. The risk of adverse events was increased substantially (rate ratio, 3.37; 95 percent confidence interval, 1.60 to 7.10) among patients with increased levels of P-glycoprotein in tumor cells, as compared with patients who did not have increased levels of P-glycoprotein in tumor cells. CONCLUSIONS: In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/análise , Neoplasias Ósseas/química , Osteossarcoma/química , Adolescente , Adulto , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/patologia , Neoplasias Ósseas/cirurgia , Terapia Combinada , Intervalo Livre de Doença , Extremidades , Feminino , Humanos , Imuno-Histoquímica , Masculino , Necrose , Osteossarcoma/tratamento farmacológico , Osteossarcoma/patologia , Osteossarcoma/cirurgia , Prognóstico , Modelos de Riscos ProporcionaisRESUMO
Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Biomarcadores Tumorais/metabolismo , Proteínas de Neoplasias/metabolismo , Osteossarcoma/metabolismo , Adolescente , Adulto , Distribuição por Idade , Idoso , Criança , Pré-Escolar , Intervalo Livre de Doença , Resistência a Múltiplos Medicamentos/fisiologia , Resistencia a Medicamentos Antineoplásicos/fisiologia , Feminino , Imunofluorescência , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Osteossarcoma/tratamento farmacológico , Osteossarcoma/secundário , Prognóstico , Resultado do TratamentoRESUMO
BACKGROUND: The availability of Ki-67 monoclonal antibody has opened new possibilities for an extensive analysis of cell kinetics in human neoplasms. Ki-67 antibody reveals a nuclear antigen that is expressed in proliferating but not in quiescent cells. Although the reliability of Ki-67 immunostaining has been evaluated in different tumor types, little information has been reported on bone neoplasms. METHODS: Cell proliferation, as determined by Ki-67 expression, was measured by immunofluorescence on representative cytospins obtained from 205 patients with bone tumors. In each sample, the percentage of Ki-67-positive cells was quantified on at least 500 cells and expressed as Ki-67 labeling index (LI). RESULTS: Ki-67 LI was lower in benign and low grade lesions as compared with high grade malignant lesions. A correlation between Ki-67 LI and histologic grade was observed in osteosarcoma and chondrosarcoma. In osteosarcoma, among the 43 primary lesions included in this study, 30 patients, all treated with the same regimen of chemotherapy and limb-salvage surgery, were selected to establish the prognostic significance of cell proliferation. The Ki-67 labeling was higher in patients with a good histologic response to chemotherapy. However, at a 24-month follow-up, a worse prognosis was associated with a higher proliferative activity, whereas no correspondence was found between the histologic response to preoperative chemotherapy and the disease free survival, suggesting that in high grade osteosarcoma the biologic aggressiveness expressed by high levels of Ki-67 LI may be clinically more relevant than the responsiveness to antineoplastic agents. CONCLUSIONS: In bone tumors, the level of Ki-67 expression correlates with the level of malignancy and is diagnostically and prognostically useful.
Assuntos
Antígenos de Neoplasias/metabolismo , Neoplasias Ósseas/patologia , Proteínas de Neoplasias/metabolismo , Proteínas Nucleares/metabolismo , Adolescente , Adulto , Biomarcadores Tumorais/metabolismo , Neoplasias Ósseas/química , Neoplasias Ósseas/imunologia , Divisão Celular , Criança , Condrossarcoma/química , Condrossarcoma/imunologia , Condrossarcoma/patologia , DNA de Neoplasias/análise , Feminino , Citometria de Fluxo , Seguimentos , Humanos , Antígeno Ki-67 , Masculino , Osteossarcoma/química , Osteossarcoma/imunologia , Osteossarcoma/patologia , PrognósticoRESUMO
The Colony-Stimulating Factors (CSFs) are undergoing clinical trials for their ability to stimulate the regeneration of bone marrow in patients receiving anticancer chemotherapy. However, the reported effects on the growth of tumor cell lines of different derivations, including osteosarcoma, raise the possibility that the use of these cytokines may induce proliferative effects also in residual tumor cells. In this study, we have used a panel of 12 human osteosarcoma (2 cell lines and 10 primary cultures) and 7 Ewing's sarcoma cell lines (5 cell lines and 2 primary cultures) to evaluate the presence of the G-CSF receptor by RT-PCR and the effects of recombinant Human (rHu) G-CSF on their in vitro growth ability. RT-PCR did not reveal the presence of G-CSF receptor band in any of the osteosarcoma or Ewing's cell lines examined. Moreover, after exposure to rHuG-CSF, no significant stimulatory or inhibitory effects were observed in any of the cell lines. Therefore, G-CSF may be safely used to stimulate marrow regeneration after high-dose chemotherapy both in osteosarcoma and in Ewing's sarcoma.
RESUMO
N-methylformamide (NMF), a powerful differentiating agent, has been extensively used in experimental and preclinical cancer chemotherapy studies, alone or in association with conventional anti-cancer drugs. To evaluate the use of this molecule in the treatment of osteosarcoma (OS), we have analyzed the effects of NMF and doxorubicin (DXR) on DXR-sensitive and -resistant human OS cell lines. Our study shows that NMF exerts remarkable effects on cell proliferation and, in Saos-2 and SARG cells, also induces differentiation, as shown by increasing alkaline phosphatase activity. Moreover, NMF increases the cytotoxic activity of DXR when administered after the drug, in both DXR-sensitive and -resistant cells. However, when this agent is given before DXR, it enhances P-glycoprotein expression in U-2 OS cell lines. This over-expression is associated with reduced DXR accumulation within cells and with significant enhancement of resistance to DXR.
Assuntos
Antineoplásicos/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias Ósseas/tratamento farmacológico , Proteínas de Transporte/fisiologia , Doxorrubicina/farmacologia , Formamidas/farmacologia , Glicoproteínas de Membrana/fisiologia , Osteossarcoma/tratamento farmacológico , Membro 1 da Subfamília B de Cassetes de Ligação de ATP , Antineoplásicos/administração & dosagem , Antineoplásicos/toxicidade , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Doxorrubicina/administração & dosagem , Doxorrubicina/farmacocinética , Interações Medicamentosas , Resistência a Medicamentos , Ensaios de Seleção de Medicamentos Antitumorais , Formamidas/administração & dosagem , Formamidas/toxicidade , Humanos , Osteossarcoma/metabolismo , Osteossarcoma/patologia , Frações Subcelulares/metabolismo , Células Tumorais Cultivadas , Verapamil/administração & dosagem , Verapamil/farmacologiaRESUMO
Multidrug resistant variants of two human osteosarcoma cell lines (U-2 OS and Saos-2) were selected by continuous exposure to doxorubicin. The in vitro and in vivo growth characteristics of these sublines as well as the expression of osteoblastic markers and of some surface antigens were analyzed. Resistant variants showed a higher doubling time and a lower cloning efficiency, and a lower metastatic ability after i.v. injection than corresponding parental cell lines. All the sublines showed overexpression of p-glycoprotein (referred to as p170). The level of expression of this protein in the different cell lines was directly related to the degree of resistance as shown by the in vitro sensitivity to doxorubicin and other multidrug-related drugs. In sublines showing the highest levels of resistance (over 300-fold), p170 overexpression was associated with mdr 1 gene amplification. These are the first multidrug resistant human osteosarcoma cell lines ever reported. They may be used as a model for further investigations into the mechanisms of drug resistance in osteosarcoma and as a standard for the assessment of chemosensitivity in clinical samples.
Assuntos
Osteossarcoma/patologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP , Animais , Proteínas de Transporte/genética , Proteínas de Transporte/fisiologia , Doxorrubicina/farmacologia , Resistência a Medicamentos/genética , Imunofluorescência , Histocitoquímica , Humanos , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/fisiologia , Camundongos , Camundongos Nus , Modelos Biológicos , Metástase Neoplásica , Osteossarcoma/tratamento farmacológico , Osteossarcoma/genética , Ploidias , RNA Mensageiro/genética , Células Tumorais Cultivadas/efeitos dos fármacos , Verapamil/farmacologiaRESUMO
The interactions between cells and the extracellular matrix (EM) have important effects on tumor invasion and metastasis. Osteosarcoma (OS) is a highly metastatic tumor, secondary lesions occurring early in the natural history of the disease. Despite the clinical relevance of disseminated disease in this neoplasia, the metastatic ability and other features related to the metastatic phenotype have not been extensively investigated in human OS cells. In this study the expression of bone matrix proteins, of their receptors, and the ability to adhere to and grow on some EM components in vitro were examined in human OS cell lines and related to their tumorigenic and metastatic potential in vivo. A significantly higher expression of integrin subunits alpha2, alpha5 and alpha6, a better-organized surface expression of fibronectin and laminin, and a lower alkaline phosphatase (ALP) activity was accompanied by a higher ability to grow in vitro on EM components and to produce tumors in nude mice. On the other hand, no relationship was found between these features and the metastatic ability. Therefore, tumorigenicity of human OS cells might be related to an overexpression of some integrins and to a peculiar expression of some bone matrix proteins, possibly associated with distinct differentiative levels. Further investigations on clinical material will possibly help defining the actual prognostic value of these parameters.